BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 28528936)

  • 1. Efficacy of non-carbapenem antibiotics for pediatric patients with first febrile urinary tract infection due to extended-spectrum beta-lactamase-producing Escherichia coli.
    Abe Y; Inan-Erdogan I; Fukuchi K; Wakabayashi H; Ogawa Y; Hibino S; Sakurai S; Matsuhashi K; Watanabe Y; Hashimoto K; Ugajin K; Itabashi K
    J Infect Chemother; 2017 Aug; 23(8):517-522. PubMed ID: 28528936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin.
    Cho YH; Jung SI; Chung HS; Yu HS; Hwang EC; Kim SO; Kang TW; Kwon DD; Park K
    Int Urol Nephrol; 2015 Jul; 47(7):1059-66. PubMed ID: 26026972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased community-acquired upper urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in children and the efficacy of flomoxef and cefmetazole.
    Horie A; Nariai A; Katou F; Abe Y; Saito Y; Koike D; Hirade T; Ito T; Wakuri M; Fukuma A
    Clin Exp Nephrol; 2019 Nov; 23(11):1306-1314. PubMed ID: 31428892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasmid-mediated AmpC beta-lactamase-producing Escherichia coli causing urinary tract infection in the Auckland community likely to be resistant to commonly prescribed antimicrobials.
    Drinkovic D; Morris AJ; Dyet K; Bakker S; Heffernan H
    N Z Med J; 2015 Mar; 128(1410):50-9. PubMed ID: 25829039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of cefoxitin versus carbapenem in febrile male urinary tract infections caused by extended spectrum beta-lactamase-producing Escherichia coli: a multicenter retrospective cohort study with propensity score analysis.
    Senard O; Lafaurie M; Lesprit P; Nguyen Y; Lescure X; Therby A; Fihman V; Oubaya N; Lepeule R
    Eur J Clin Microbiol Infect Dis; 2020 Jan; 39(1):121-129. PubMed ID: 31512147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of reflex fosfomycin susceptibility testing on the utilization of carbapenems for definitive extended-spectrum β-lactamase Escherichia coli urinary tract infection treatment.
    Deemer K; Grey J; Fronczek C; Marr K
    Am J Health Syst Pharm; 2020 Nov; 77(Supplement_4):S105-S110. PubMed ID: 32840305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aminoglycoside therapy for childhood urinary tract infection due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.
    Han SB; Lee SC; Lee SY; Jeong DC; Kang JH
    BMC Infect Dis; 2015 Oct; 15():414. PubMed ID: 26464143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended spectrum beta lactamase producing organisms causing urinary tract infections in Sri Lanka and their antibiotic susceptibility pattern -A hospital based cross sectional study.
    Fernando MM; Luke WA; Miththinda JK; Wickramasinghe RD; Sebastiampillai BS; Gunathilake MP; Silva FH; Premaratna R
    BMC Infect Dis; 2017 Feb; 17(1):138. PubMed ID: 28187754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Activity of Fosfomycin Against Extended-Spectrum Beta-Lactamase-Producing Isolates of Enterobacteriaceae Recovered from Urinary Tract Infections: A Single-Center Study Over a Period of 12 Years.
    Aris P; Boroumand MA; Rahbar M; Douraghi M
    Microb Drug Resist; 2018 Jun; 24(5):607-612. PubMed ID: 29064348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carbapenem versus fosfomycin tromethanol in the treatment of extended-spectrum beta-lactamase-producing Escherichia coli-related complicated lower urinary tract infection.
    Senol S; Tasbakan M; Pullukcu H; Sipahi OR; Sipahi H; Yamazhan T; Arda B; Ulusoy S
    J Chemother; 2010 Oct; 22(5):355-7. PubMed ID: 21123160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Fosfomycin susceptibility of urinary Escherichia coli isolates producing extended-spectrum beta-lactamase according to CLSI and EUCAST recommendations].
    Cağan Aktaş S; Gençer S; Batırel A; Hacıseyitoğlu D; Ozer S
    Mikrobiyol Bul; 2014 Oct; 48(4):545-55. PubMed ID: 25492650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pediatric community acquired urinary tract infections due to extended-spectrum beta-lactamase versus non-extended-spectrum beta-lactamase producing bacteria.
    Alsubaie MA; Alsuheili AZ; Aljehani MN; Alothman AA; Alzahrani AS; Mohammedfadel HA; Alnajjar AA
    Pediatr Int; 2023; 65(1):e15620. PubMed ID: 37735838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of community-onset healthcare-associated and hospital-acquired urinary infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and antimicrobial activities.
    Saltoglu N; Karali R; Yemisen M; Ozaras R; Balkan II; Mete B; Tabak F; Mert A; Hondur N; Ozturk R
    Int J Clin Pract; 2015 Jul; 69(7):766-70. PubMed ID: 25683907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the Treatment Outcome of Piperacillin-Tazobactam versus Carbapenems for Patients with Bacteremia Caused by Extended-Spectrum β-Lactamase-Producing Escherichia coli in Areas with Low Frequency of Coproduction of OXA-1: a Preliminary Analysis.
    Hoashi K; Hayama B; Suzuki M; Sakurai A; Takehana K; Enokida T; Takeda K; Ohkushi D; Doi Y; Harada S
    Microbiol Spectr; 2022 Aug; 10(4):e0220622. PubMed ID: 35916524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial susceptibility and mechanisms of fosfomycin resistance in extended-spectrum β-lactamase-producing Escherichia coli strains from urinary tract infections in Wenzhou, China.
    Bi W; Li B; Song J; Hong Y; Zhang X; Liu H; Lu H; Zhou T; Cao J
    Int J Antimicrob Agents; 2017 Jul; 50(1):29-34. PubMed ID: 28456703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary Tract Infections in Kidney Transplant Patients Due to Escherichia coli and Klebsiella pneumoniae-Producing Extended-Spectrum β-Lactamases: Risk Factors and Molecular Epidemiology.
    Espinar MJ; Miranda IM; Costa-de-Oliveira S; Rocha R; Rodrigues AG; Pina-Vaz C
    PLoS One; 2015; 10(8):e0134737. PubMed ID: 26237422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluation of antibiotic treatments for urinary tract infections in the elderly, especially regarding the effect on extended spectrum β-lactamase producing (ESBL-) Escherichia coli: A comparison between meropenem and alternatives].
    Yamamoto A; Yamasaki K
    Nihon Ronen Igakkai Zasshi; 2015; 52(2):153-61. PubMed ID: 25994987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergence of fosfomycin resistance among isolates of Escherichia coli harboring extended-spectrum and AmpC β-lactamases.
    Bahramian A; Eslami G; Hashemi A; Tabibi A; Heidary M
    Acta Microbiol Immunol Hung; 2018 Mar; 65(1):15-25. PubMed ID: 29137487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The risk factors, antimicrobial resistance patterns, and outcomes associated with extended-spectrum β-lactamases-Producing pathogens in pediatric urinary tract infection.
    He XT; Chang CN; Yu CH; Wang CC
    Pediatr Neonatol; 2024 May; 65(3):242-248. PubMed ID: 37951832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of Multidrug Resistant Extended-Spectrum Beta-Lactamase-Producing Escherichia coli among Uropathogens of Pediatrics in North of Iran.
    Rezai MS; Salehifar E; Rafiei A; Langaee T; Rafati M; Shafahi K; Eslami G
    Biomed Res Int; 2015; 2015():309478. PubMed ID: 26064896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.